Sponsor Responsibilities in ICH E6(R3) 

What E6(R3) means for sponsor accountability, oversight, and documentation — plus a practical sponsor responsibilities infographic.

Sponsor Responsibilities in ICH E6(R3) 

What E6(R3) means for sponsor accountability, oversight, and documentation — plus a practical sponsor responsibilities infographic.
Cyntegrity logo – Risk-Based Quality Management Solutions

Decoding Sponsor Responsibilities in ICH E6(R3)

E6(R3) reinforces a message sponsors have heard before — but with sharper clarity:
You may delegate tasks, but you cannot delegate responsibility.

 

Oversight now means visible, traceable decision-making and active collaboration with CROs and sites, not passive expectation management.

Where The Guideline Raises the Bar

Responsibility Area

What E6(R3) Emphasizes

What Sponsors Must Demonstrate

Quality Management

Quality must be built into trial plans

CtQ factors are defined and reflected in design, monitoring focus, and decisions

Risk Review & Response

Risks must be continuously evaluated

Documented adjustments (not just static plans)

CRO & Vendor Oversight

Delegation ≠ transfer of accountability

Evidence of oversight, not assumptions or summaries

Participant Safety

Protection must be proactive

Consistent safety signal surveillance and response rationale

Documentation & Traceability

Decisions must be reviewable

Why each action was taken — not just what was done

Common Concern: “How Much Documentation Is Enough?”

E6(R3) is less about more documentation and more about clear justification.
The question is not “Did we do it?”

 

but “Can we show how and why we made each decision?”

Bottom Line

For sponsors, E6(R3) is not just regulatory guidance — it is a roadmap for confident oversight.
Organizations that treat oversight as a continuous dialogue rather than a final audit step are already well on their way.

Sponsor Responsibilities Infographic

In the MyRBQM® Portal, CtQ priorities, risk decisions, and oversight actions are linked automatically — providing the traceability E6(R3) expects.

Stay Informed with Us

Risk-based quality management in 2026

Risk-based quality management in 2026: how ICH E6(R3) defines RBQM, where practice diverges, and what regulators now expect in clinical trials....
Diagram illustrating the FDA Total Product Lifecycle (TPLC) management approach for AI and machine learning devices, showing a continuous cycle of design, validation, submission, monitoring, and update.

FDA AI Guidance 2025 Interactive Visualizer

Explore how FDA’s 2025 AI guidance shapes lifecycle oversight for AI-enabled medical software through interactive regulatory scenarios....

Media Inquiries

Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.

Sponsor Responsibilities ICH E6(R3)

Sponsor Responsibilities ICH E6(R3)